Excimer 308 nm for Focal Vitiligo (Face/Neck): Protocols, Response Kinetics, and Combinations
Key Takeaways Targeted therapy ideal for focal lesions, active edges, and facial/neck sites; enables high local dose while sparing uninvolved […]
facial vitiligo
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways Pimecrolimus 1% cream showed superiority to vehicle on facial endpoints (F-VASI) over ~12–24 weeks in split-face and parallel-arm
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Face/neck consistently show the best repigmentation with tacrolimus 0.1%; early perifollicular islands predict response. Acral (hands/feet) and longstanding
Excimer 308 nm in Vitiligo: Focal Therapy for Face/Neck and Acral Margins
Key Takeaways Targeted 308 nm is effective for limited facial/neck lesions and expanding edges of patches. Acral sites (hands/feet) respond slower;
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways For facial vitiligo, pimecrolimus 1% shows superiority over placebo on F-VASI and global assessments in several RCTs/split-face designs.
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Facial/neck lesions show the highest response rates to tacrolimus 0.1%, often with early perifollicular islands of repigmentation. Trunk/extremities
NB-UVB + Tacrolimus vs NB-UVB Alone in Vitiligo: Randomized Controlled Trial
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many